^
BIOMARKER:

FLT3-ITD mutation

i
Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
Entrez ID:
FLT3-ITD mutation
AML
midostaurin
Sensitive: A2 - Guideline
FLT3-ITD mutation
AML
gilteritinib
Sensitive: A2 - Guideline
FLT3-ITD mutation
AML
sorafenib
Sensitive: A2 - Guideline
FLT3-ITD mutation
AML
cytarabine
Resistant: B - Late Trials
FLT3-ITD mutation
AML
venetoclax + azacitidine
Sensitive: B - Late Trials
FLT3-ITD mutation
AML
bortezomib
Sensitive: C2 – Inclusion Criteria
FLT3-ITD mutation
AML
quizartinib
Sensitive: C2 – Inclusion Criteria
FLT3-ITD mutation
AML
TP-0903
Sensitive: C2 – Inclusion Criteria
FLT3-ITD mutation
AML
PHI-101
Sensitive: C2 – Inclusion Criteria
FLT3-ITD mutation
AML
pexidartinib
Sensitive: C2 – Inclusion Criteria
FLT3-ITD mutation
AML
quizartinib + RAIN-32
Sensitive: C2 – Inclusion Criteria
FLT3-ITD mutation
AML
venetoclax + quizartinib
Sensitive: C2 – Inclusion Criteria
FLT3-ITD mutation
AML
gilteritinib + quizartinib + fingolimod
Sensitive: C3 – Early Trials
FLT3-ITD mutation
AML
FLT3 inhibitor
Sensitive: C3 – Early Trials
FLT3-ITD mutation
AML
cytarabine
Resistant: C3 – Early Trials
FLT3-ITD mutation
AML
venetoclax
Sensitive: C3 – Early Trials
FLT3-ITD mutation
AML
ponatinib
Sensitive: C3 – Early Trials
FLT3-ITD mutation
AML
venetoclax + gilteritinib
Sensitive: C3 – Early Trials
FLT3-ITD mutation
AML
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
FLT3-ITD mutation
AML
selumetinib
Resistant: C3 – Early Trials
FLT3-ITD mutation
AML
venetoclax + ruxolitinib
Sensitive: C3 – Early Trials
FLT3-ITD mutation
AML
sorafenib + gilteritinib
Sensitive: C3 – Early Trials
FLT3-ITD mutation
AML
FF-10101
Sensitive: C3 – Early Trials
FLT3-ITD mutation
AML
DA
Sensitive: C4 – Case Studies
FLT3-ITD mutation
AML
bortezomib + verteporfin
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
Max-40279
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
FLT3 inhibitor + LIMK2 inhibitor
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
ABBV-744
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
venetoclax + SM09419
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
venetoclax + IACS-010759
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
midostaurin + SM09419
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
dasatinib
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
CPI-0610
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
APG-115 + HQP1351
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
sorafenib + GMI-1359
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
sorafenib + melatonin
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
melatonin
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
venetoclax + midostaurin
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
LAM 003
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
ARO-002 + Wu-5
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
gilteritinib + CUDC-907
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
venetoclax + AMG 176
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
quizartinib + PLX51107
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
PLX51107
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
SM09419
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
quizartinib + LY2510924
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
venetoclax + LAM 003
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
palbociclib
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
pacritinib + SB939
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
olaparib
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
venetoclax + ONO-7475
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
quizartinib + Lys05
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
FLT3 inhibitor + BET inhibitor
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
quizartinib + IMGN779
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
AIU2008
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
APG-2575 + HQP1351
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
gilteritinib + AMG 176
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
quizartinib + STF-083010
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
STF-083010
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
Bcl2 inhibitor + Tyrosine kinase inhibitor
Sensitive: D – Preclinical
FLT3-ITD mutation
AML
quizartinib + PF-04691502
Sensitive: D – Preclinical